Zh.Nevrol.Psikhiatr.Im S.S.Korsakova 2008;108(2):27-30
It's about getting your body working for you again
Ipamorelin shows minimal effect No appetite stimulation: Unlike ghrelin itself, Ipamorelin does not significantly activate hunger pathways in published studies Published Research on Ipamorelin Study Model Key Finding Raun et al., 1998 (Eur J Endocrinol) Swine/Human Selective GH release without cortisol/prolactin elevation Johansen et al., 1999 Human (Phase I/II) Dose-response relationship with no significant adverse effects Bowers et al., 2004 Review Comparative analysis of GHRP selectivity profiles Head-to-Head Comparison Research Factor CJC-1295 Ipamorelin Receptor Target GHRH-R GHS-R1a (Ghrelin receptor) Signaling Pathway cAMP / PKA PLC / Calcium GH Release Pattern Amplifies natural pulsatile release Induces acute GH pulse Cortisol Impact Minimal Minimal Prolactin Impact Minimal Minimal Research Focus Sustained GH elevation models Selective/clean GH pulse models Typical Research Duration No DAC: 30min half-life / DAC: days ~2 hour half-life Why Researchers Study Them Together The combination of a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) is well-documented in published literature
Thus, non-specific leaking of the proteins through the barrier (Pardridge and Mietus, 1980
Peer Reviewed Data and Research At the same time that regulatory agencies were conducting their reviews, other researchers began publishing their findings
What Research Shows About Maximum Therapeutic Doses Clinical trials for weight management typically compare 2.4 mg weekly (the highest approved dose in brand-name formulations) against placebo and lower doses
